Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
Duke-NUS Medical School, Singapore.
J Gastroenterol Hepatol. 2019 Aug;34(8):1296-1315. doi: 10.1111/jgh.14648. Epub 2019 Jul 1.
The Asia-Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia-Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.
亚太炎症性肠病工作组在亚太胃肠病学会的支持下于菲律宾宿务成立，目标是改善亚洲地区炎症性肠病的治疗水平。本共识是与亚洲克罗恩病和结肠炎组织合作开展的。随着生物制剂和生物类似药的应用越来越广泛，有必要对现有文献进行回顾，并就如何在亚洲引入生物制剂和生物类似药结合传统治疗溃疡性结肠炎和克罗恩病达成共识。这些声明还涉及到药物遗传学如何影响溃疡性结肠炎和克罗恩病的治疗，并就反应监测和恢复反应策略提供指导。最后，审查还包括如何管理与乙型肝炎和结核病（亚洲常见感染）相关的治疗。这些声明是由炎症性肠病工作组的成员采用改良 Delphi 流程编写和投票的。这些声明并非包罗万象，随着新数据的不断出现，可能会进行修订。
